Litcius/Paper detail

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study

Thomas Martin, Yi Lin, Mounzer Agha, Adam D. Cohen, Myo Htut, A. Keith Stewart, Parameswaran Hari, Jesús G. Berdeja, Saad Z. Usmani, Tzu‐Min Yeh, Yunsi Olyslager, Jenna D. Goldberg, Jordan M. Schecter, Deepu Madduri, Carolyn C. Jackson, William Deraedt, Katharine S. Gries, John Fastenau, Jeremiah Trudeau, Muhammad Akram, Lida Pacaud, Andrzej Jakubowiak, Sundar Jagannath

2022The Lancet Haematology44 citationsDOI

Topics & Concepts

MedicineInternal medicineMultiple myelomaQuality of life (healthcare)Refractory (planetary science)Clinical trialCancerChimeric antigen receptorOncologyImmunotherapyAstrobiologyNursingPhysicsCAR-T cell therapy researchMultiple Myeloma Research and TreatmentsImmunotherapy and Immune Responses
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study | Litcius